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Abstract
Background—Epidemiologic studies found childhood mumps might protect against ovarian
cancer. To explain this association, we investigated whether mumps might engender immunity to
ovarian cancer through antibodies against the cancer-associated antigen MUC1 abnormally
expressed in the inflamed parotid gland.
Methods—Through various health agencies, we obtained sera from 161 cases with mumps parotitis.
Sera were obtained from 194 healthy controls. We used an ELISA to measure anti-MUC1 antibodies
and electro-chemiluminescence assays to measure MUC1 and CA 125. Log-transformed
measurements were analyzed by t-tests, generalized linear models, and Pearson or Spearman
correlations. We also conducted a meta-analysis of all published studies regarding mumps and
ovarian cancer.
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Results—Adjusting for assay batch, age, and sex, the level of anti-MUC1 antibodies was
significantly higher in mumps cases compared to controls (p = 0.002). Free circulating levels of CA
125, but not MUC1, were also higher in cases (p = 0.02). From the meta-analysis, the pooled odds
ratio estimate (and 95% CI) for the mumps and ovarian cancer association was 0.81 (0.68–0.96) (p
= 0.01).
Conclusion—Mumps parotitis may lead to expression and immune recognition of a tumor-
associated form of MUC1 and create effective immune surveillance of ovarian cancer cells that
express this form of MUC1.
Keywords
Ovarian cancer; Mumps parotitis; MUC1; CA125
Introduction
In one of the earliest case–control studies of ovarian cancer, West observed that women with
the disease were less likely to report having had mumps compared to women with benign
ovarian cysts [1], suggesting that childhood mumps might protect against the subsequent
development of ovarian cancer. Eight additional observational studies addressing mumps and
ovarian cancer were published [2–9], and in all but two [2,9], controls were more likely to
report a history of mumps than cases, suggesting that mumps might be associated with lower
ovarian cancer risk. Despite this intriguing observation, biologic mechanisms were not
pursued. As time passed and with the introduction of mumps vaccination in the late 1960s, the
association between mumps and ovarian cancer was rendered seemingly irrelevant and largely
forgotten.
Recently, we proposed and tested a new hypothesis that can unite many apparently unrelated
ovarian cancer risk factors [10]. Protective risk factors may work through events that raise
immunity against normal cell proteins that may be abnormally overexpressed in injured or
inflamed tissues and also later on nascent ovarian cancer cells making them targets of effective
immune surveillance. As an example of such molecules, we have studied the cell surface
glycoprotein and tumor-associated antigen, mucin 1 (MUC1). MUC1 is a product of the mucin
family of genes that also includes MUC16 (CA125). MUC1 is normally expressed at low levels
and, in an extensively glycosylated form, on epithelia of the genito-urinary, respiratory, and
digestive tracts as well as breast ducts. It is overexpressed in a hypoglycosylated
(immunogenic) form in most adenocarcinomas, including breast and ovarian tumors. We
previously reported that (acute) inflammatory events that affect tissues that normally express
MUC1, like a tubal ligation or a breast mastitis, found to protect against ovarian cancer, might
do so by causing overexpression of the hypoglycosylated form of MUC1, leading to an immune
response and immune memory for the type of MUC1 later found on ovarian cancer cells [10].
Just as the presence of anti-MUC1 antibodies in patients with cancer at diagnosis may be
associated with a more favorable disease prognosis [11], pre-existing antibodies might prevent
disease in the first place.
Salivary glands also express a low level of the fully glycosylated form of MUC1 on apical
ductal surfaces [12]. We reasoned that abnormal expression of MUC1 during a mumps
infection might induce lasting anti-MUC1 immunity (measured by anti-MUC1 antibodies),
giving a mechanistic explanation to the phenomenological association between mumps and
ovarian cancer. In the current study, we sought to test this hypothesis by comparing levels of
anti-MUC1 antibodies (as well as MUC1 and CA 125 antigens) in samples obtained from
patients diagnosed with mumps versus healthy controls.
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Methods
Mumps cases
We surveyed several Regional and State Health Departments about the availability of
specimens for research purposes from cases with a mumps infection. Our final sample included
a total of 161 cases with clinically diagnosed mumps parotitis from four different agencies,
three contributed 149 paired samples (during the acute and convalescent phase of the infection)
and one contributed single samples (Table 1). Thirty-nine paired samples were available from
cases with clinically diagnosed mumps parotitis who reported to the Health Protection Agency
Centre for Infections (London, UK). Fifty-two paired samples were obtained from the
Specialist Virology Centre of Edinburgh collected between fall 2004 and mid 2005. Cases were
predominantly young adults and older teenagers born before routine mumps immunization was
introduced in the regions. Additionally, 58 paired serum samples collected from cases with
confirmed or probable mumps infection during a 2007 outbreak were received from The Queen
Elizabeth II Health Sciences Centre (Nova Scotia, Canada). These included 35 paired sera from
laboratory-confirmed cases of mumps and 23 paired sera from cases with symptomatic parotitis
but low mumps titer. Of these 23 samples, 18 had an epidemiologic link to a laboratory-
confirmed case. Finally, 12 one-time samples collected between 2000 and 2008 and obtained
some time during mumps parotitis were provided by the North Dakota Department of Public
Health. All samples were shipped to our laboratory on dry ice via overnight courier.
Institutional Review Boards (IRBs) associated with the local Health departments or hospitals
approved release of specimens without identifying information. Only age, sex, and mumps
viral titer (where available) were linked to the specimens that were therefore considered
anonymized and exempt by IRBs at the Brigham and Women’s Hospital and University of
Pittsburgh.
Controls
A total of 194 controls were obtained from four sites (Table 1). Twelve samples were received
from the Department of Immunology at the University of Pittsburgh. These were University
volunteers who were recruited to provide information on the distribution of “normal” anti-
MUC1 antibody levels to compare against response to a MUC1 peptide vaccine in various
patients with cancer. Single serum samples from 67 participants of a health screening program
(who did not have mumps parotitis) were obtained from the Queen Elizabeth II Health Sciences
Centre (Nova Scotia, Canada). In the course of surveying State Laboratories, the Illinois
Department of public health indicated they could not provide mumps specimens but could
supply 39 specimens from individuals who were asymptomatic but seeking to assess the status
of their immunity to mumps. Finally, 76 samples were collected from healthy volunteers in
Boston from Research Blood Components, a commercial blood bank in Boston, MA where all
blood donors must have been free of any symptoms suggestive of a viral illness. As with the
mumps cases, all specimens were de-identified and linked only to age at collection and sex.
Assays for anti-MUC1 antibodies
Anti-MUC1 antibodies were measured against a synthetic 100-mer MUC1 peptide
corresponding to five tandem repeats of the MUC1 polypeptide core repeat region [10]. The
polypeptide mimics the hypoglycosylated state of MUC1 found in ovarian cancer. Briefly,
MUC1-coated Immulon wells (Dynax, Chantilly, VA) and peptide-negative plates were
incubated overnight and washed three times with PBS before addition of 100 μl of 2.5% bovine
serum albumin in PBS. Serially diluted plasma (1:40–1:80 in PBS) was added to MUC1-coated
plates and incubated at room temperature. Plates were washed 5× with 100 μl PBS and 0.1%
Tween 20 detergent. Alkaline phosphatase-labeled goat anti-human polyvalent IgM, IgG, IgA
(50 μl) (Sigma-Aldrich, St. Louis, MO) diluted 1:1,000 was added before plates were again
washed 5× with PBS–Tween. Alkaline phosphatase substrate pNPP (100 μl) (Sigma-Aldrich)
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was added. Plates were incubated before the stop solution (0.5 mol/l NaOH) was added. We
used the MRX Revelation plate reader (Thermo Labsystems, Chantilly, VA) to read absorbance
values at 405–410 nm, which were subtracted from absorbance values obtained from antigen-
negative plates to account for non-specific binding.
Laboratory personnel were blinded to case–control status of the samples. Blood specimens
from cases and controls as well as paired samples from the same participants were assayed on
the same plate, which also included masked quality control samples (three to five replicates
per plate). Samples were assayed in two batches. Batch 1 included samples from London and
controls from the University of Pittsburgh, which were assayed in triplicate and in four dilutions
(1:40, 1:80, 1:160, and 1:320). Average values across triplicates were reported for each sample.
In order to increase the number of specimens per assay plate and thus decrease inter-plate
variability, samples in batch 2 (which included all the remaining study specimens) were assayed
only in two dilutions (1:40 and 1:80). Triplicates of each sample were assayed on different
plates, and average values of triplicates were reported for each sample. The coefficients of
variation (CV) for the batch 1 and 2 positive controls were 18 and 4%, respectively. The
Spearman rank correlation between the 1:40 and 1:80 dilutions was 0.95. Readings at 1:40
were used for the current analysis.
Assays for CA 125 and MUC1
Serum levels of CA 125 and MUC1 were measured (blinded to case status) using electro-
chemiluminescence (ECL) assays and Imager 2400 (Meso Scale Discovery, Gaithersburg, MD,
USA). The ECL platform allows assays using very small volumes and has been validated
against traditional ELISA [13]. The linearity ranges were 1.2–5,000 U/ml for the CA 125 and
0.98–4,000 mU/ml for the MUC1 assay. The serum samples were tested undiluted for the CA
125 and diluted 1:200 for the MUC1 assay. A positive quality control (QC) sample was run
on each plate in duplicate. The QC sample had a mean CA 125 concentration of 450.47 U/ml
and a mean MUC1 concentration of 63.73 U/ml. The coefficient of variation was calculated
as 100* (SD/average) for each assay plate and between plates. The intra-plate CV% for CA
125 varied from 2.2 to 13.1% with inter-plate CV = 9.1%. The intra-plate CV% for MUC1
varied from 0 to 4.7% with inter-plate CV = 11.0%.
Meta-analysis
We searched the literature for studies that examined the association between history of mumps
parotitis and subsequent development of ovarian cancer. On June 2009, we searched
MEDLINE (via PubMed), Web of Science and EMBASE using the search terms mumps,
parotitis, ovarian neoplasms, ovarian cancer. No limits on publication dates or on language
were imposed. This search yielded a total of 34 references, nine of which referred to original
contributions. Of these, one [1] did not provide estimates for the association between mumps
parotitis and ovarian cancer and, therefore, was not included in the meta-analysis, which
included a total of eight case–control studies [2–9]. We estimated a summary odds ratio of
ovarian cancer and the associated 95% confidence interval across studies using a random
effects model, and statistical heterogeneity was assessed using I2 and Cochran Chi-square
statistics [14].
Statistical analysis
The anti-MUC1 antibody, MUC1, and CA 125 distributions were skewed right, so we first log
transformed the values to normalize their distributions. We examined geometric mean levels
by case–control status and used t-tests to assess differences by case–control status stratified by
laboratory batch number, site, age, and sex. We used linear regression to examine the mean
difference in log-transformed anti-MUC1 antibody or MUC1 and CA 125 antigen levels,
adjusted for age, sex, and laboratory batch. For sites with continuous mumps titer data available
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(London and Edinburgh), we used Spearman rank correlations to assess the relationship
between titer levels and anti-MUC1 antibody levels. Pearson correlations were used to examine
the relationship between anti-MUC1 antibody levels and MUC1 antigen levels. The SAS
version 9.1 statistical package (SAS Institute, Cary, NC) was used for all analyses. All p values
are two-sided with significance levels set at <0.05.
Results
We identified eight case–control studies that provided odds ratios for the association between
mumps parotitis and ovarian cancer [2–8]. In all but two of these studies [2], controls were
more likely to report a history of mumps than cases. From these studies, using a random effects
model, we estimated that the overall risk of ovarian cancer associated with history of mumps
parotitis was 0.81 with 95% confidence interval of 0.68–0.96 (p = 0.01), suggesting that mumps
is significantly and inversely associated with ovarian cancer risk (Fig. 1). A fixed effects model
produced similar study estimates. The I2 test for statistical heterogeneity indicated small
variability among studies that could not be explained by chance, 11%, and the Cochran’s Q
statistic for heterogeneity was not significant (p = 0.30).
No significant differences in anti-MUC1 antibody levels were observed between acute and
convalescent specimens from those sites providing paired samples (see footnote to Table 2).
Therefore, the values were averaged for each subject. Geometric mean anti-MUC1 antibody
levels are described in Table 2 by batch and mumps status. There was a clear batch effect for
the mumps samples run first with London cases and Pittsburgh controls; both groups having
lower mean levels compared to the larger number of specimens run in the second batch. Some
variation was noted in anti-MUC1 antibody levels in mumps cases by the source of the
specimens contributed to batch 2, but this reflected differences in the composition of the
samples by age and sex further illustrated in Table 2. In general, males had lower levels of anti-
MUC1 antibodies than females, and antibody levels appeared to decline with age in the male
cases and controls. In all age and sex categories from batch 2, the levels of anti-MUC1
antibodies were higher in the mumps cases compared to controls (p = 0.003). As illustrated in
Table 3, mumps was a significant predictor of higher anti-MUC1 antibody levels after
adjustment for age and sex in generalized linear models either restricted to batch 2 data (p =
0.002) or in a second model which included batch 1 data, as well as a variable for batch in the
model (p = 0.002). The models confirmed that age and sex were also significant predictors
with higher anti-MUC1 antibody levels in younger individuals and women.
We also examined whether circulating levels of CA125 or MUC1 antigens differed between
mumps cases and controls. For many of the samples, including all of those from London,
Edinburgh, and Pittsburgh, there was insufficient volume remaining after the anti-MUC1
antibody measurement for the CA125 and MUC1 measurements. In univariate analyses, no
significant differences were observed for MUC1 levels but, as shown in Table 4, mumps cases
had higher CA125 levels than controls (p = 0.02). In a multivariate linear regression model
with log-transformed CA125 as the dependent variable, neither age (coefficient = 0.004, p
value = 0.38) nor sex (coefficient = −0.006, p value = 0.95) was significantly associated with
CA125, but mumps cases had mean log-transformed CA125 levels that were significantly
higher than controls, on average (p = 0.03). These results are similar to the t-tests shown in
Table 4. No significant correlations were observed between mumps viral titers supplied for the
London and Edinburgh cases and anti-MUC1 antibody levels (data not shown). These were
the same cases with insufficient volume to measure MUC1 and CA 125, so the correlations of
the antigens with viral titers could not be examined. We examined the correlation between anti-
MUC1 antibody levels and MUC1 antigen levels. There was a weak but significant inverse
correlation between antigen and antibody levels for mumps cases (r = −0.24, p = 0.05), but not
controls (r = −0.09, p = 0.21).
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Discussion
In this study, we found that sera from individuals during (or just after) symptomatic mumps
parotitis have a significantly higher level of anti-MUC1 antibodies than sera from controls
without active parotitis. Showing the relevance of this observation to ovarian cancer clearly
requires background data that would link mumps, ovarian cancer, and anti-MUC1 antibodies.
Concerning the mumps and ovarian cancer association, we performed a meta-analysis of all
published original reports to obtain an overall estimate of the effect. In eight observational
studies addressing the association, the summary odds ratio was 0.81 with 95% confidence
limits of 0.68–0.96 (p = 0.01), suggesting a 19% decrease in risk of ovarian cancer associated
with history of mumps parotitis. One of the studies not finding an odds ratio<1 also did not
find an association with parity [2], and the second study in which the association was null [9]
was the most recent of the studies and would have included many more subjects who had been
vaccinated for the mumps. Conversely, several of the key studies (which had looked at other
associations besides the mumps) confirmed well-established findings, like protection with
pregnancies and oral contraceptive use [3,6–8]. While prospective studies related to mumps
would have been desirable, studies two through eight are likely to constitute the only pre-
vaccination era epidemiologic data we will ever have related to this association.
Despite the epidemiologic evidence that mumps might reduce the risk of ovarian cancer, this
association has largely been ignored, probably due to the lack of a plausible biologic
explanation. We have presented data here in support of an immunological basis for the
association. A protective effect of mumps parotitis on ovarian cancer risk can be explained
under a model related to immunity against the surface glycoprotein, MUC1. Events affecting
tissues that normally express MUC1 might confer protection because of injury to the tissue
causing expression and presentation of a tumor-like (less glycosylated) form of MUC1 to the
immune system [10]. This would allow immune recognition of the protein core of MUC1 and
generation of an immune response similar to that which occurs with cancer [15,16]. Since
MUC1 is expressed in normal salivary glands, acute inflammation of this tissue with mumps
would be expected to induce changes in MUC1 expression and glycosylation similar to that
which has been reported for other tissues undergoing inflammation [17–21]. Thus, our
observation that anti-MUC1 antibodies are elevated in individuals with mumps is consistent
with the interpretation that mumps infection could elicit an immune response to later protect
against ovarian cancer.
We began this study with the expectation that, in mumps cases with paired sera, we would find
higher MUC1 levels in the acute specimen and higher anti-MUC1 antibody levels in the
convalescent specimen. The fact that neither was observed may reflect lack of detail on the
timing of blood collections in relation to onset of symptoms. Alternatively, the fact that anti-
MUC1 antibody levels were similar (but higher than controls) in both the acute and
convalescent sera could be explained if this were not the first time that the mumps cases had
seen an inflammatory type of MUC1. In this circumstance, a much more rapid immune
response would be expected and might have occurred because of prior inflammatory conditions
involving the genito-urinary, respiratory, digestive tract, or breast ducts—tissues which all
express MUC1. MUC1 antigen itself was not elevated in cases compared to controls in either
the acute or convalescent specimens. Saliva, if it had been available, might have been a better
body fluid to look for MUC1, but it is also possible that the presence of anti-MUC1 antibodies
interfered with measurement of MUC1 since immune complexes involving MUC1 and
antibodies against it have been described [22]. Supporting this possibility was an inverse
correlation between anti-MUC1 antibody levels and MUC1 antigen levels in cases (but not
controls) noted in our presentation of the results of Table 4. Interestingly, CA 125 was
significantly elevated in sera from the mumps cases compared to controls. CA 125 is expressed
in salivary gland tumors [23], but we could find no reports of its expression in normal salivary
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glands. The low volume of mumps specimens precluded measurement of immune complexes
or anti-CA125 antibody levels.
There are many limitations of this study, not the least of which was the difficulty of obtaining
specimens from individuals with mumps parotitis which limited the size of this study. The
samples we obtained were collected between 2000 and 2008 in various public health agencies
and were stored under variable conditions (Table 1). Although mumps is now reportable in
many regions, we have no way of knowing whether the cases that come to public health
attention are representative of mumps infection in the community or a more selected group.
Information on precisely when during the course of the infection the samples were collected
was limited, and titer data were available from only two sites (London and Edinburgh). Because
of the anonymized nature of the case and control specimens, we were unable to correct for
potential confounders, other than age and gender. Age could be a key confounder, since we
previously reported that anti-MUC1 antibody levels may decline with age [10]. While cases
were more likely than controls to be younger and to be male, adjustment by these variables
revealed that confounding by age and sex did not account for the relationships between mumps
and anti-MUC1 antibodies, CA125, or MUC1 levels. The small size of this study should not
have produced an artifactual association between mumps and anti-MUC1 antibody (or CA125
levels) but certainly could have affected the precision of our estimate of the effect.
Regarding controls, we are certain they did not have an active mumps infection, but it was a
diverse group which included university volunteers for the London cases in batch 1 and, in
batch 2, individuals without mumps in Illinois who were tested for immunity and blood bank
controls from Boston. Community-matched controls were only available for the Nova Scotia
subjects in batch 2. Despite this, the levels of anti-MUC1 antibodies in all control groups from
batch 2 were very similar and nearly identical to the Nova Scotia controls.
Another limitation was variability in the assay from batch 1 to batch 2. To decrease inter-plate
variability after running batch 1, we increased the number of unique specimens per plate for
batch 2, which may have contributed to the batch differences. However, despite batch variation,
both batches suggested higher antibody levels in mumps cases compared to controls. Moreover,
analyses including and excluding batch 1 yielded a similar result.
The epidemiology of mumps parotitis has obviously changed dramatically in the last 40 years.
Mumps parotitis was a very common illness in infants and children prior to 1970. With now
close to universal vaccination except in the third world, mumps has become a disease of adults
who were either born too early for routine vaccination or who have lost immunity after
vaccination. For this reason, inferences about the consequences of parotitis on MUC1 immunity
based on observations from the specimens tested here may not be generalizable to what might
have occurred with childhood infection before vaccination programs began. We point out,
however, that the anti-MUC1 antibody response was most robust in younger women suggesting
that childhood infection, as would have occurred in the past, might have been the optimum
time for engendering immunity against ovarian cancer.
Clearly, mumps vaccination only creates anti-viral antibodies and would not lead to anti-MUC1
antibodies, which we show here require an active parotitis. If it is true that symptomatic mumps
protected against ovarian cancer through an immune reaction, a logical consequence is that we
might expect an increased incidence of ovarian cancer as symptomatic mumps parotitis
infections have decreased through vaccination. In a paper examining incidence patterns for
ovarian cancer from 1978 to 1998, rates of invasive serous, endometrioid, and clear cell tumor
increased over this time period among white females [24]. Endometrioid and clear cell cancers
are the types of ovarian cancer that we found were most strongly linked to the conditions we
proposed might be mediated through anti-MUC1 antibodies [10]. The above incidence data
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may be confounded by diagnostic trends, but re-examination of these disease rates with more
recent data and a focus on the birth cohorts most likely to have been vaccinated should be
undertaken.
Prior to vaccination, mumps was generally a mild illness but could have serious sequelae
including orchitis and sterility, meningitis and deafness, and pancreatitis. Nevertheless, our
study suggests there could also have been unanticipated long-term anticancer benefits of a
mumps infection, such as we have described in this paper. Understanding the scope of and
basis for the potential benefits of childhood infections may allow immunologists to duplicate
the beneficial effects at the same time that vaccination provides the means for avoiding a natural
infection and its possible immediate consequences. Further study of individuals going through
a mumps infection, especially with a focus on mucin immunity, may provide clues to
mechanisms for duplicating the beneficial effects of mumps parotitis suggested by this study.
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Fig. 1.
Odds ratios from studies of mumps and ovarian cancer and the summary odds ratio
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Table 3
Generalized linear models with anti-MUC1 antibody level as the dependent variable
Coefficienta p Valuea
Model 1: Batch 2 (excluding London and Pittsburgh)
 Age (years) −0.005 0.07
 Sex (male vs. female) −0.19 0.005
 Mumps (yes vs. no) 0.21 0.002
Model 2: Batch 1 and 2 (including London and Pittsburgh)
 Age (years) −0.005 0.03
 Sex (male vs. female) −0.20 0.001
 Batch (1 vs. 2) 0.65 < 0.0001
 Mumps (yes vs. no) 0.19 0.002
a
Each coefficient for models 1 and 2 is adjusted for the other variables in the models
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